Cardiology journal最新文献

{"title":"Unique coincidence of mitral valve prolapse and left ventricular hypertrabeculation in a patient with ventricular arrythmia.","authors":"Anna M Imiela, Katarzyna Kurnicka, Dorota Piotrowska-Kownacka, Marek Gołębiowski, Piotr Pruszczyk","doi":"10.5603/cj.102843","DOIUrl":"10.5603/cj.102843","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"32 4","pages":"440-441"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperkalemia: Is it always about slow rhytm?","authors":"Łukasz Leśnowolski, Aleksandra Dudek, Jacek Lewandowski, Piotr Jędrusik, Piotr Abramczyk","doi":"10.5603/cj.103837","DOIUrl":"10.5603/cj.103837","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"32 4","pages":"442-443"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete intramyocardial course of dominant left anterior descending coronary artery and its branches: \"Myocardial bridging of the whole ventricular coronary tree\".","authors":"Paolo Ciliberti, Davide Curione, Luca Borro, Teresa Santangelo, Alessio Perazzolo, Aurelio Secinaro","doi":"10.5603/cj.98620","DOIUrl":"https://doi.org/10.5603/cj.98620","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"32 1","pages":"102-103"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction - 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators' viewpoint.","authors":"Jacek Kubica, Piotr Adamski, Jolita Badariene, Marc Bonaca, Piotr Buszman, Rahima Gabulova, Robert Gajda, Tobias Geisler, Robert Gil, Diana A Gorog, Paul A Gurbel, Tomasz Hajdukiewicz, Bartosz Hudzik, Stefan James, Young-Hoon Jeong, Adam Kern, Wacław Kochman, Aldona Kubica, Wiktor Kuliczkowski, Przemysław Magielski, Piotr Niezgoda, Małgorzata Ostrowska, Paolo Raggi, Uzeyir Rahimov, Grzegorz Skonieczny, Jolanta M Siller-Matula, Giuseppe Specchia, Łukasz Szarpak, Paweł Szymański, Udaya Tantry, Julia Umińska, Eliano Pio Navarese","doi":"10.5603/cj.99973","DOIUrl":"10.5603/cj.99973","url":null,"abstract":"<p><p>The 2023 ESC guidelines changed previously recommended a strategy of early treatment in patients with STEMI. Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy (Class IIb, Level of evidence B). However, the available scientific evidence justifies a personalized approach differentiating the indications for pre-treatment with oral P2Y12 receptor inhibitors depending on the concomitant administration of opioids. In our opinion, in patients undergoing primary PCI not treated with opioids, pre-treatment with an oral P2Y12 receptor inhibitor should be applied, while in patients undergoing primary PCI treated with opioids, pre-treatment with an oral P2Y12 receptor inhibitor should be considered.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"189-194"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of an antibacterial envelope on cardiac implantable device-related infection - A real-world analysis from a tertiary center.","authors":"Nadine Molitor, Vera Graup, Daniel Hofer, Pascal Rüegg, Deniza Avdi, Ardan M Saguner, Alexander Breitenstein, Jan Steffel","doi":"10.5603/cj.100458","DOIUrl":"10.5603/cj.100458","url":null,"abstract":"<p><strong>Background: </strong>Infections related to cardiac implantable electronic devices (CIED) are associated with significant morbidity and mortality. Antibiotic-eluting envelopes have been introduced as a technology to prevent CIED infections. The aim of this study was to evaluate the effectiveness of the antibacterial envelope in the real-world population of a tertiary center.</p><p><strong>Methods: </strong>This cohort study includes consecutively enrolled patients undergoing a device procedure from 01/2014 to 12/2020 at the University Hospital in Zurich. During period A (01/2014-12/2019) antibacterial envelopes were not used, whereas during period B (01/2020-12/2020) antibacterial envelopes were used in all device interventions. Follow-up was conducted by assessing all available patient records from patient visits and hospitalization.</p><p><strong>Results: </strong>1757 patients (male 70.5%, mean age 67.1 ± 16 years), were analyzed during a follow-up of 24 months. In 302 patients (17.2%) an antibacterial envelope was used. The overall occurrence of a device infection was low (n = 15, 0.85%). Factors that were associated with the incidence of an infection were not undergoing a primary implantation procedure (p = 0.024) and a CRT-P/D intervention (p = 0.022). There was no difference in the rate of infection between patients in whom a bacterial envelope was implanted vs. those in whom it was not used (0.6 vs. 0.9%, p = 0.693).</p><p><strong>Conclusion: </strong>In a contemporary cohort of consecutive, unselected patients undergoing a device intervention at a large tertiary care center, the rate of device infection was low and not significantly different with vs. without the use of an antibacterial envelope. The data have important practical as well as economic implications for physicians performing such procedures.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"301-307"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multivessel disease treated with a double-kiss culotte and chronic total occlusion with support of quantative flow ratio, intravascular ultrasound and shockwave intravascular lithotripsy.","authors":"Mateusz Barycki, Piotr Rola, Adrian Włodarczak, Szymon Włodarczak, Yoshinobu Onuma, Patrick W Serruys, Maciej Lesiak","doi":"10.5603/cj.95950","DOIUrl":"10.5603/cj.95950","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"32 1","pages":"98-99"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the effect of the antiPCSK9 vaccine on systemic inflammation and oxidative stress in an experimental mouse model.","authors":"Amir Abbas Momtazi-Borojeni, Maciej Banach, Amirhossein Sahebkar","doi":"10.5603/cj.100585","DOIUrl":"10.5603/cj.100585","url":null,"abstract":"<p><strong>Background: </strong>To investigate whether the antiPCSK9 vaccine can affect the CRP and oxidative stress (OS) during acute systemic inflammation.</p><p><strong>Methods: </strong>Male albino mice were randomly divided into three groups: non-treated mice (the sham group), treated with a nonspecific stimulator of the immune response - Freund's complete adjuvant (CFA; the CFA group), and vaccinated mice treated with CFA (the vaccine group). The vaccine group was subcutaneously immunized with the antiPCSK9 formulation, 4 × in bi-weekly intervals. To induce inflammation, all mice were subjected to the CFA challenge after the vaccination plan. The hsCRP level and OS status were evaluated by a mouse CRP ELISA kit and the pro-oxidant antioxidant balance (PAB) assay, respectively.</p><p><strong>Results: </strong>The vaccine induced a high-titter IgG antiPCSK9 antibody, which was accompanied with a significant PCSK9 reduction (-24.7% and -28.5% compared with the sham and CFA group, respectively), and the inhibition of PCSK9/LDLR interaction (-27.8% and -29.4%, respectively). hsCRP was significantly increased in the vaccine and CFA groups by 225% and 274% respectively, when compared with the sham group; however, it was non-significantly decreased (-18%; p = 0.520) in the vaccine group in comparison with the CFA group. The PAB values indicated that OS was significantly increased in the CFA group (by 72.7%) and the vaccine group (by 76%) when compared to the sham group; however, there was no significant difference in the PAB values between the vaccine and CFA groups.</p><p><strong>Conclusion: </strong>The antiPCSK9 vaccine failed to significantly reduce the serum hs-CRP and OS induced in the CFA-challenged albino mice.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"73-82"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiation of non-ST-segment elevation myocardial infarction from unstable angina using coronary computed tomography angiography: the role of imaging features and pericoronary adipose tissue radiomics.","authors":"Yang Lu, Qing Wang, Haifeng Liu, Qi Liu, Siqi Wang, Wei Xing","doi":"10.5603/cj.98559","DOIUrl":"10.5603/cj.98559","url":null,"abstract":"<p><strong>Background: </strong>To ascertain the diagnostic value of radiomic features of pericoronary adipose tissue (PCAT) and other coronary computed tomography angiography (CCTA) parameters for differentiating non-ST-segment-elevation myocardial infarction (NSTEMI) from unstable angina (UA).</p><p><strong>Methods: </strong>This study included NSTEMI and UA patients (n = 102 each). The radiomic features of PCAT were selected according to the intraclass correlation coefficient, Pearson's coefficient, the t test, and least absolute shrinkage and selection operator. Six classifiers-random forest, support vector machine, naive Bayes, K-nearest neighbors, extreme gradient boosting, and light gradient boosting machine (LightGBM)-were used to build radiomics models, and the best were selected. Four CCTA parameter models, encapsulating plaque parameters (model 1), plaque parameters + fatty attenuation index (FAI) (model 2), plaque parameters + CT fractional flow reserve (CT-FFR) (model 3), and plaque parameters + CT-FFR + FAI (model 4), were constructed. Finally, we established a fusion model (nomogram) with all CCTA parameters and radiomics model scores. All models were compared regarding their performance.</p><p><strong>Results: </strong>The LightGBM radiomics model achieved the highest AUC. Among CCTA parameter models, only model 4 achieved a predictive performance similar to that of the radiomics model in the training and test cohorts (AUC = 0.904 vs. 0.898 and 0.860 vs. 0.877). The combined model (nomogram) showed greater predictive efficacy (AUC = 0.963, 0.910) than model 4 or the radiomics model.</p><p><strong>Conclusion: </strong>The PCAT-based radiomics model accurately distinguishes between NSTEMI and UA, with similar diagnostic performance as the model that combined all the significant CCTA parameters. The nomogram integrating CCTA parameters and the radiomic score has good clinical application prospects.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"291-300"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spinal cord stimulation in the treatment of refractory angina pectoris: 25-year clinical experience at a single center.","authors":"Jan Naar, Dusan Urgosik, Petr Volf, Pavel Michalek, Petr Neuzil","doi":"10.5603/cj.99015","DOIUrl":"10.5603/cj.99015","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"328-331"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline left ventricular ejection fraction predicts the magnitude of improvement in patients taking sacubitril/valsartan.","authors":"José-Manuel Rubio-Campal, Carlos Rodriguez Lopez, Carla Lázaro Rivera, Francisco de Asís Díaz Cortegana, Loreto Bravo Calero, Cristina Aguilera Agudo, José María Romero-Otero, José Tuñón Fernández","doi":"10.5603/cj.104310","DOIUrl":"10.5603/cj.104310","url":null,"abstract":"<p><strong>Background: </strong>Sacubitril/valsartan (S/V) improve left ventricular ejection fraction (LVEF) in heart failure patients, but the magnitude of improvement may depend on baseline values.</p><p><strong>Methods: </strong>We analyzed whether baseline LVEF can predict its improvement in patients with LVEF ≤ 45% receiving S/V. Patients were divided into 4 groups (G) according to baseline LVEF (G1: ≤ 20%; G2: 21-30%; G3: 31-40%; G4: 41-45%).</p><p><strong>Results: </strong>We included 256 patients (age 73 ± 12 years; 73% male; 174 ischemic cardiomyopathy [CM], 82 nonischemic CM) and assessed LVEF at S/V initiation and at 6 and 12 months of therapy. Baseline LVEF (%) values (overall 30.9 ± 8.6) were: G1: 17.3 ± 3.3; G2: 27.5 ± 2.4; G3: 35.5 ± 2; G4: 44.4 ± 1. LVEF increased in 62% of patients, reaching 34.3 ± 10.4% and 35.5 ± 11.2% at 6 and 12 months, respectively (p < 0.001). A significantly higher absolute LVEF increase was found in Groups 3 (7.2 ± 4.3) and 4 (4.2 ± 3.05) than in Groups 1 (0.6 ± 1.5) and 2 (3.5 ± 1.5), in women (5.9 ± 4.4 vs. 4.1 ± 4.5; p < 0.001), with high S/V doses (7.4 ± 4.7 vs. 4.3 ± 4.4; p < 0.001), and in nonischemic CM (6.3 ± 4.9 vs. 3.8 ± 4.2; p < 0.001). On multivariate analysis, female sex (OR 2.18; 95% CI [1.06-4.48]; p = 0.034), high dose (OR 3.38; 95% CI [1.10-10.34]; p = 0.033), and baseline LVEF > 30% (OR 8.62; 95% CI [4.69-15.82]; p = 0.001) were significant predictors of LVEF improvement.</p><p><strong>Conclusions: </strong>LVEF improvement with S/V depends on baseline values, sex, and dose.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"270-277"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}